siRNA-based Nanocarriers for Targeted Therapy in Prostate Cancer: Implications for Male Fertility Preservation

Area of Science:

• Oncology
• Nanotechnology
• Biotechnology

Background:

• Prostate cancer (PC) presents a significant global health challenge, with conventional treatments often leading to therapeutic resistance, toxicity, and male infertility.
• Small interfering RNA (siRNA) therapeutics offer precise targeting of oncogenes and tumor-promoting pathways, but clinical application is hindered by issues with stability, delivery, and cellular uptake.

Purpose of the Study:

• To review the potential of biomarker-targeted siRNA codelivery systems for prostate cancer treatment.
• To explore how nanocarriers can overcome the limitations of siRNA delivery.
• To consider the impact on reproductive health and identify future directions for fertility-preserving therapies.

Main Methods:

• Literature review focusing on siRNA-based therapeutics, nanocarrier systems (lipid-based, exosome-based, polymeric), and their application in prostate cancer.
• Analysis of strategies for biomarker-targeted codelivery of siRNA.
• Evaluation of translational barriers and their impact on clinical application and reproductive health.

Main Results:

• Nanocarriers demonstrate potential to enhance the stability, specificity, and efficacy of siRNA therapeutics for prostate cancer.
• Biomarker-targeted codelivery strategies are emerging as a promising approach.
• Addressing translational barriers is crucial for clinical success and patient quality of life.

Conclusions:

• Nanocarrier-mediated siRNA codelivery holds significant promise for advancing prostate cancer treatment.
• Future research should focus on optimizing delivery systems and addressing reproductive health concerns to develop more effective and patient-centered therapies.